The International Prognostic Index and the Follicular Lymphoma International Prognostic Index are widely used for the risk assessment of follicular lymphoma (FL). Although molecular studies have provided insight into the biology of FL, no molecular marker has impacted on treatment stratification. Because TP53 mutations are associated with poor prognosis in hematologic malignancies, we investigated the prognostic value of TP53 mutation at diagnosis in FL. Heterozygous TP53 mutation was detected in 12 of 185 (6%) analyzed cases. Mutation was associated with older age (P = .02) and higher International Prognostic Index score (P = .04). On multivariate analysis, TP53 mutation correlated with shorter progression-free survival (P < .001) and overall survival (P = .009). TP53 mutation was associated with low expression of the immune-response 1 gene expression signature (P = .016) and with an unfavorable gene expression-based survival predictor score (P < .001), demonstrating for the first time that molecular features of the malignant cell may correlate with the nature of the immune response in FL.

Follicular lymphoma (FL) is characterized by episodes of progression alternating with periods of remission and is associated with a median survival of 8 to 10 years.1,2  However, a proportion of patients die within the first 2 years; furthermore, histologic transformation may occur, dramatically reducing overall survival (OS).3,4  Despite the introduction of immunochemotherapy, which has improved outcome,5-7  the management of high-risk patients remains challenging. The International Prognostic Index (IPI) and the Follicular Lymphoma International Prognostic Index are widely used for risk assessment in FL,8  the latter retaining its predictive capacity with the current use of upfront immunochemotherapy.9  Newer molecular studies have provided insight into the biology of FL, and as yet no molecular markers have impacted on treatment stratification. Gene expression profiling studies have identified 2 prognostic signatures, immune-response 1 (IR1) and immune-response 2 (IR2), both based on nonmalignant tumor-infiltrating cells.10  The IR1 signature is a molecular correlate of a T cell–rich tumor microenvironment, whereas the IR2 signature reflects a microenvironment enriched in myeloid-lineage cells. A survival predictor score was formed from these expression signatures, high values of which indicated enrichment for the IR2 signature and unfavorable OS, which has been confirmed recently.11 

Mutations in TP53 are frequent in cancer12  and hematologic malignancies where they correlate with unfavorable prognosis and chemotherapy resistance.13-15 TP53 mutation has been reported in 10% to 20% of various histologic subtypes of non-Hodgkin lymphoma.16  In FL TP53 mutation occurs infrequently at diagnosis and usually in association with transformation.17-20  We therefore set out to clarify the role of TP53 mutation in a large series of previously untreated FL patients and assess its impact on patient prognosis and clinical outcome.

Patient information

DNA from 191 untreated patients with FL presenting between 1974 and 2001 was obtained through the Lymphoma/Leukemia Molecular Profiling Project; 185 cases were analyzed for TP53 mutation. These samples were chosen because they were fully characterized molecularly.10  Clinical data were available in 172 cases. Approval to use clinical material for mutation analysis was obtained from the London Research Ethics Committee and East London and the City London Research Ethics Committee, and their stipulations regarding patient consent, confidentiality, and data protection were followed. The ethics submission covering this project is 06/Q0605/69. This study was conducted in accordance with the Declaration of Helsinki.

TP53 mutation detection

Because our previous data20  showed poor correlation between TP53 protein status by immunohistochemistry and mutation status, and in keeping with the recommendation from the International Agency for Research on Cancer (IARC) TP53 database,21  we screened genomic DNA samples for DNA sequence variants using high-resolution melting curve analysis followed by bidirectional sequencing. Primers were designed to amplify the coding sequence and flanking 3′ and 5′ splice sites of exons 5 to 8 of TP53 using Primer322  (primers and conditions are available on request). Analysis was restricted to these exons as they harbor 94.2% of all somatic mutations in the most recent IARC database.23  Melting profiles of the polymerase chain reaction products were determined using DHPLC Melt program (Genome Technology Center, Stanford University, Stanford, CA; http://insertion.stanford.edu/melt.html). Melting curve analysis was carried out using a HR96 LightScanner and data collected and normalized for fluorescence and temperature shift using LightScanner software (Idaho Technology, Salt Lake City, UT). All samples with melting profiles different from wild-type control samples were bidirectionally sequenced, using the primers (earlier in same paragraph) and the Big Dye Terminator kit on the Applied Biosystems 3730 Genetic Analyser (Applied Biosystems, Foster City, CA). Data were analyzed by visual inspection of electropherograms and Mutation Surveyor software (SoftGenetics, State College, PA). Single nucleotide polymorphism array analysis and conventional comparative genomic hybridization were used to assess the frequency of del 17p in this cohort.

Statistical analysis

Association with clinical characteristics was investigated by Fisher exact test for (not ordered) categorical data, t test for normally distributed continuous data, and Mann-Whitney U test for ordered data. OS was defined as the time from diagnosis to death, or for patients remaining alive, the time from diagnosis to last contact. Progression-free survival (PFS) was defined as the time from diagnosis to first progression, transformation or death from any cause, or for patients remaining alive and disease free, the time from diagnosis to last contact. Transformation was defined histologically (n = 27) or clinically (n = 12) with signs including: rapid nodal or extranodal growth, unusual extranodal sites, or sudden rise in lactic dehydrogenase. Kaplan-Meier survival estimates were obtained and the log-rank test used to compare differences between the mutated and wild-type subgroups. Multivariate Cox regression was used to determine whether mutation remained independently predictive of PFS and OS after adjusting for clinical variables. Significance was set at P less than .05. Gene expression correlation was performed as previously described.10 

TP53 mutation was detected in 12 of 185 (6%) cases of diagnostic FL. All were heterozygous. Eleven mutations were missense (exon 5 (1), exon 7 (5), and exon 8 (5)), and a single mutation arose in the splice site of intron 7 (Table 1). All mutations were previously reported in the IARC TP53 mutation database.12  Single nucleotide polymorphism and comparative genomic hybridization analysis showed 5 cases with loss of heterozygosity involving the TP53 locus (data not shown), suggesting that del 17p is a rare event at diagnosis.

Table 1

Analysis of TP53 mutations in FL and correlation with tumor stage and clinical outcome

Patient no.Age at diagnosis, yGenomic no.*Predicted amino acid no.LocationPredicted effectPredicted TP53 functionDisease stage at presentationInitial treatmentPFS, moOS, y
45 g.13216 T>A p.H179Q Exon 5 Missense Nonfunctional IIe Single-agent chemotherapy 10 7.7 
Not known g.14028 A>G p.Y234C Exon 7 Missense Nonfunctional Not known Multiagent chemotherapy 53 4.5 
47 g.14057 G>A p.G244S Exon 7 Missense Nonfunctional III Multiagent chemotherapy radiotherapy 11 5.0 
71 g.14060 G>A p.G245S Exon 7 Missense Nonfunctional II Radiotherapy 21 11.9 
64 g.14060 G>T p.G245C Exon 7 Missense Nonfunctional IV Expectant management 24 9.8 
59 g.14061 G>T p.G245V Exon 7 Missense Nonfunctional IV Multiagent chemotherapy 0.5 
65 g.14111 T>G NA Intron 7 Splice site Splice III Multiagent chemotherapy 11 0.9 
78 g.14486 C>T p.R273C Exon 8 Missense Nonfunctional III Multiagent chemotherapy 12 7.7 
53 g.14487 G>A p.R273H Exon 8 Missense Nonfunctional III Radiotherapy 25 4.4 
10 63 g.14487 G>A p.R273H Exon 8 Missense Nonfunctional II Multiagent chemotherapy 16 2.3 
11 63 g.14513 C>T p.R282W Exon 8 Missense Nonfunctional IV Multiagent chemotherapy 15 2.0 
12 75 g.14517 G>A p.R283H Exon 8 Missense Functional IV Multiagent chemotherapy 15 1.3 
Patient no.Age at diagnosis, yGenomic no.*Predicted amino acid no.LocationPredicted effectPredicted TP53 functionDisease stage at presentationInitial treatmentPFS, moOS, y
45 g.13216 T>A p.H179Q Exon 5 Missense Nonfunctional IIe Single-agent chemotherapy 10 7.7 
Not known g.14028 A>G p.Y234C Exon 7 Missense Nonfunctional Not known Multiagent chemotherapy 53 4.5 
47 g.14057 G>A p.G244S Exon 7 Missense Nonfunctional III Multiagent chemotherapy radiotherapy 11 5.0 
71 g.14060 G>A p.G245S Exon 7 Missense Nonfunctional II Radiotherapy 21 11.9 
64 g.14060 G>T p.G245C Exon 7 Missense Nonfunctional IV Expectant management 24 9.8 
59 g.14061 G>T p.G245V Exon 7 Missense Nonfunctional IV Multiagent chemotherapy 0.5 
65 g.14111 T>G NA Intron 7 Splice site Splice III Multiagent chemotherapy 11 0.9 
78 g.14486 C>T p.R273C Exon 8 Missense Nonfunctional III Multiagent chemotherapy 12 7.7 
53 g.14487 G>A p.R273H Exon 8 Missense Nonfunctional III Radiotherapy 25 4.4 
10 63 g.14487 G>A p.R273H Exon 8 Missense Nonfunctional II Multiagent chemotherapy 16 2.3 
11 63 g.14513 C>T p.R282W Exon 8 Missense Nonfunctional IV Multiagent chemotherapy 15 2.0 
12 75 g.14517 G>A p.R283H Exon 8 Missense Functional IV Multiagent chemotherapy 15 1.3 

PFS indicates progression-free survival; OS, overall survival; and NA, not applicable.

*

Genomic numbers refer to reference sequence U94788.

Predicted amino acid numbers refer to a translation of NM000546.

Predicted structural and functional characteristics of the mutations were obtained from the mutation validation tool of the IARC TP53 Mutation Database.

The major clinical characteristics of the 172 patients are summarized in Table S1 (available on the Blood website; see the Supplemental Materials link at the top of the online article). TP53 mutation occurred more frequently in older patients (P = .02) and those with higher IPI (P = .04). Mutated patients were treated heterogeneously (Table 1); and although most responded well, responses were frequently of short duration (median, 15 months; range, 4-53 months). This resulted in inferior PFS (log-rank, P < .001) and OS (log-rank, P < .001) for patients with mutation (Figure 1A and 1B, respectively).

Figure 1

Survival. (A) Progression-free survival by TP53 mutational status. (B) Overall survival by TP53 mutational status.

Figure 1

Survival. (A) Progression-free survival by TP53 mutational status. (B) Overall survival by TP53 mutational status.

Close modal

Multivariate analyses confirmed that TP53 mutation was predictive for shorter PFS when adjusted for IPI (hazard ratio [HR] = 3.6; 95% confidence interval [CI], 1.8-7.2, P < .001), or for age and stage (HR = 3.4; 95% CI, 1.7-6.7, P < .001). However, the effect of TP53 mutation on OS was significant only after adjustment for IPI (HR = 2.7; 95% CI, 1.3-5.6, P = .009) but not when adjusted for age and stage. Transformation data were available on 142 cases. There was no association seen between TP53 mutation and transformation in this group; 3 of 11 patients with TP53 mutation transformed in contrast to 36 of 131 with normal TP53 status (Table S1; P = 1.0).

TP53 mutation was associated with low expression of the IR1 gene expression signature (P = .016), but not with the IR2 signature (P = .53). The survival predictor score formed from these 2 signatures, higher values of which are associated with an unfavorable prognosis, was associated with TP53 mutation (P = .001); 11 of 12 mutated cases were within the upper 51% of the survival predictor scores. Incorporating TP53 status into the IR1/IR2-based survival model did not, however, lead to an improved predictor (P = .21), perhaps reflecting the strong association of TP53 mutation status with the survival predictor score. These findings provide the first suggestion that molecular features of the malignant cell may correlate with the host immune response, as reflected by the IR1 and IR2 signatures in keeping with the complex interaction between the tumor and its microenvironment in FL.10 

This group of patients was treated heterogeneously; because TP53 mutation is associated with high-risk disease, this raises the issue of whether these patients should receive more aggressive therapy. Because none of the mutated cases received upfront chemo-immunotherapy, it remains to be determined whether rituximab will improve survival in this group. Patients with chronic lymphocytic leukemia and TP53 abnormalities have not seen improvements in survival with rituximab.24  Therapeutic strategies could include alemtuzumab or lenalidomide, which have demonstrated activity in chronic lymphocytic leukemia patients with TP53 dysfunction. Although TP53 mutation is more frequent in older patients, 4 of 12 mutated cases here were younger than 60 years, and nonmyeloablative allogeneic stem cell transplantation may be an option. Radiotherapy would not be predicted to prolong responses,25  as the majority of mutations observed here were nonfunctional (Table 1).

These results suggest that TP53 screening could be incorporated into the design of clinical trials in FL. If mutation is validated as a high-risk genetic marker, investigational treatments could be considered in this group of patients.

An Inside Blood analysis of this article appears at the front of this issue.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

The work was supported by grants from Cancer Research UK, the Medical Research Council, and NIH SPEC grant 5U01CA114778. D.O. is supported by a Medical Research Council Clinical Research Fellow grant. C.O. is a Cancer Research UK Barts-Cambridge Molecular Pathology Clinical Research Fellow.

Contribution: D.O. designed the study, analyzed data, and wrote the paper; D.O., C.O., and C.T. performed research; R.W., F.M., E.C., J.G., and G.W. analyzed data; A.R., G.O., L.M.R., E.B.S., N.J., E.C., T.C.G., W.C.C., and R.D.G. collected data: and L.M.S., T.A.L., and J.F. designed the study and wrote the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Derville O'Shea, Centre for Medical Oncology, Barts and the London School of Medicine, Charterhouse Square, London EC1M6BQ, United Kingdom; e-mail: derville.oshea@cancer.org.uk.

1
Gallagher
 
CJ
Gregory
 
WM
Jones
 
AE
, et al. 
Follicular lymphoma: prognostic factors for response and survival.
J Clin Oncol
1986
, vol. 
4
 (pg. 
1470
-
1480
)
2
Horning
 
SJ
Natural history of and therapy for the indolent non-Hodgkin's lymphomas.
Semin Oncol
1993
, vol. 
20
 (pg. 
75
-
88
)
3
Acker
 
B
Hoppe
 
RT
Colby
 
TV
Cox
 
RS
Kaplan
 
HS
Rosenberg
 
SA
Histologic conversion in the non-Hodgkin's lymphomas.
J Clin Oncol
1983
, vol. 
1
 (pg. 
11
-
16
)
4
Bastion
 
Y
Sebban
 
C
Berger
 
F
, et al. 
Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.
J Clin Oncol
1997
, vol. 
15
 (pg. 
1587
-
1594
)
5
Liu
 
Q
Fayad
 
L
Cabanillas
 
F
, et al. 
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center.
J Clin Oncol
2006
, vol. 
24
 (pg. 
1582
-
1589
)
6
Fisher
 
RI
LeBlanc
 
M
Press
 
OW
Maloney
 
DG
Unger
 
JM
Miller
 
TP
New treatment options have changed the survival of patients with follicular lymphoma.
J Clin Oncol
2005
, vol. 
23
 (pg. 
8447
-
8452
)
7
Sacchi
 
S
Pozzi
 
S
Marcheselli
 
L
, et al. 
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.
Cancer
2007
, vol. 
109
 (pg. 
2077
-
2082
)
8
Solal-Celigny
 
P
Roy
 
P
Colombat
 
P
, et al. 
Follicular lymphoma international prognostic index.
Blood
2004
, vol. 
104
 (pg. 
1258
-
1265
)
9
Buske
 
C
Hoster
 
E
Dreyling
 
M
Hasford
 
J
Unterhalt
 
M
Hiddemann
 
W
The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome.
Blood
2006
, vol. 
108
 (pg. 
1504
-
1508
)
10
Dave
 
SS
Wright
 
G
Tan
 
B
, et al. 
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.
N Engl J Med
2004
, vol. 
351
 (pg. 
2159
-
2169
)
11
Byers
 
RJ
Sakhinia
 
E
Joseph
 
P
, et al. 
Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling.
Blood
2008
, vol. 
111
 (pg. 
4764
-
4770
)
12
Olivier
 
M
Eeles
 
R
Hollstein
 
M
Khan
 
MA
Harris
 
CC
Hainaut
 
P
The IARC TP53 database: new online mutation analysis and recommendations to users.
Hum Mutat
2002
, vol. 
19
 (pg. 
607
-
614
)
13
Prokocimer
 
M
Rotter
 
V
Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages.
Blood
1994
, vol. 
84
 (pg. 
2391
-
2411
)
14
Preudhomme
 
C
Fenaux
 
P
The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies.
Br J Haematol
1997
, vol. 
98
 (pg. 
502
-
511
)
15
Krug
 
U
Ganser
 
A
Koeffler
 
HP
Tumor suppressor genes in normal and malignant hematopoiesis.
Oncogene
2002
, vol. 
21
 (pg. 
3475
-
3495
)
16
Koduru
 
PR
Raju
 
K
Vadmal
 
V
, et al. 
Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma.
Blood
1997
, vol. 
90
 (pg. 
4078
-
4091
)
17
Sander
 
CA
Yano
 
T
Clark
 
HM
, et al. 
p53 mutation is associated with progression in follicular lymphomas.
Blood
1993
, vol. 
82
 (pg. 
1994
-
2004
)
18
Lo Coco
 
F
Gaidano
 
G
Louie
 
DC
Offit
 
K
Chaganti
 
RS
Dalla-Favera
 
R
p53 mutations are associated with histologic transformation of follicular lymphoma.
Blood
1993
, vol. 
82
 (pg. 
2289
-
2295
)
19
Symmans
 
WF
Katz
 
RL
Ordonez
 
NG
Dalton
 
H
Romaguera
 
JE
Cabanillas
 
F
Transformation of follicular lymphoma: expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation.
Acta Cytol
1995
, vol. 
39
 (pg. 
673
-
682
)
20
Davies
 
AJ
Lee
 
AM
Taylor
 
C
, et al. 
A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma.
Leukemia
2005
, vol. 
19
 (pg. 
1459
-
1465
)
21
Soussi
 
T
Beroud
 
C
Assessing TP53 status in human tumours to evaluate clinical outcome.
Nat Rev Cancer
2001
, vol. 
1
 (pg. 
233
-
240
)
22
Rozen
 
S
Skaletsky
 
H
Primer3 on the WWW for general users and for biologist programmers.
Methods Mol Biol
2000
, vol. 
132
 (pg. 
365
-
386
)
23
Petitjean
 
A
Mathe
 
E
Kato
 
S
, et al. 
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
Hum Mutat
2007
, vol. 
28
 (pg. 
622
-
629
)
24
Byrd
 
JC
Gribben
 
JG
Peterson
 
BL
, et al. 
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
J Clin Oncol
2006
, vol. 
24
 (pg. 
437
-
443
)
25
Knoops
 
L
Haas
 
R
de Kemp
 
S
, et al. 
In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma.
Blood
2007
, vol. 
110
 (pg. 
1116
-
1122
)
Sign in via your Institution